| Literature DB >> 30332800 |
Yan-Ping Huang1,2,3, Tao-Bin He4,5,6,7, Xian-Dan Cuan8,9,10, Xuan-Jun Wang11,12,13, Jiang-Miao Hu14, Jun Sheng15,16,17.
Abstract
2,3-O-acetylated-1,4-β-d-glucomannan (DOP-1-1) is a polysaccharide isolated from the stem of Dendrobium officinale. DOP-1-1 has been demonstrated to have remarkable immunomodulatory properties, but little is known about the influence of its structural diversity on bioactivity (and even less about the exact mechanism underlying its immune responses). First, DOP-1-1 was stabilized at different temperatures and pH conditions based on differential scanning calorimetry and size exclusion-chromatography⁻high-performance liquid chromatography. Then, a detailed study on the effects of DOP-1-1 on a human leukemia monocytic cell line (THP-1) under normal conditions was undertaken. DOP-1-1 promoted the translocation of nuclear factor-kappa B (NF-κB) and degradation of IκB proteins. The expression of genes and proteins closely associated with the immune, survival and apoptotic functions of NF-κB were analyzed by quantitative real-time RT-PCR. Furthermore, CCL4 and IP10 were confirmed to be the novel targets of the immune response stimulated by DOP-1-1. The phosphorylation of NF-кB was inhibited by treatment with a toll-like receptor 4 (TLR4) antagonist (TAK-242) and myeloid differentiation factor 88 (MyD88) inhibitor (ST2825). These data suggested: (i) the O-acetylated glucomannan DOP-1-1 is present in the steady state in low-pH solutions; (ii) DOP-1-1 can induce an immune response through NF-кB mediated by a TLR4 signaling pathway; and (iii) CCL4 and IP10 could be the novel targets of the immune response stimulated by O-acetylated glucomannan.Entities:
Keywords: 1,4-β-d-glucomannan; Dendrobium officinale; NF-кB; TLR4; thermal stability
Mesh:
Substances:
Year: 2018 PMID: 30332800 PMCID: PMC6222441 DOI: 10.3390/molecules23102658
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The structure of O-acetylated glucomannan according to published papers [22,24,25].
Carbohydrate and Protein Contents of Crude polysaccharide and purified O-acetylated glucomannan.
| Sample | Total Carbohydrate (% | Protein (% |
|---|---|---|
| Crude polysaccharide (DOP) | 76 | 0.002 |
| 98.9 ± 0.74 | Not Detected |
Figure 2The stability of DOP-1-1. (a) DSC scans of different concentrations of DOP-1-1 dissolved in water. (b) DSC scans of DOP-1-1 (2 mg/mL) at pH 2, pH 4, pH 6, and pH 8 solution. (c) Stability of DOP-1-1 (2 mg/mL) at 60 °C. Comparison of DOP-1-1 peak percentage at different time points for pH 2, pH 4, pH 6, and pH 8 solution. All percentage values of HPLC data are normalized against the values at 0 h.
Figure 3Effects of DOP-1-1 at different concentrations on the survival of mature macrophages differentiated from THP-1 cells by MTT assay. (a) 12 h, (b) 24 h, (c) 36 h, (d) 48 h (D25, D50, D100, D150, D300 means 25, 50, 100, 150, 300 μg/mL of DOP-1-1. The data were expressed as mean values ± SD).
Figure 4DOP-1-1 mediated immune response via NF-κB. (a) Western blot of phosphorylated NF-κB and IκBα from whole proteins. (b) Western blot for cytoplasmic and nuclear fraction: C-NF-κB and N-NF-κB represent NF-κB proteins in cytoplasm and nucleus, respectively; C-β-tubulin and N-TBP (TATA binding protein) were the internal reference for cytoplasm and nucleus, respectively. (c) Immunofluorescence of phosphorylated NF-κB.
Figure 5Interactions between DOP-1-1 and protein receptors on THP-1 cells. (a,b) Evaluation of Cell coverage on sensor surface test: QCM measurements by staining the nuclei of THP-1 cells with Hoechst33342 and visualized under a fluorescent microscope. (c) Sensograms and binding data for each DOP-1-1 and THP-1 cells. (d) Effects of DOP-1-1 on TLR4 and NF-κB protein and β-tubulin. (e) Effects of DOP-1-1 on NF-κB protein by blocking TLR4 and β-tubulin.
Figure 6Comparison of the expression profile of genes associated with NF-κB between DOP-1-1treated cells and untreated cells. (a) The effects of PDTC and bay 11-7082 (NF-κB inhibitor) on NF-κB (b) mRNA fold changing ranged from 1 to 10; (c) mRNA fold changing ranged from 10 to 150; (d) mRNA fold changing ranged from 150 to 1000; (e) mRNA fold changing ranged from 2000 to 6000. (f) DOP-1-1 down-regulated genes; (Each assay was performed in triplicate. * p < 0.05, ** p < 0.01, *** p < 0.001).
Sequences of the primers and probes used in real-time PCR assays.
| Gene Name | Forward Primer | Reverse Primer |
|---|---|---|
| β-actin | AATCTGGCACCACACCTTCTAC | ATAGCACAGCCTGGATAGCAAC |
| iNOS | TACTCCACCAACAATGGCAA | ATAGCGGATGAGCTGAGCAT |
| MCP1 | AAGCAGAA GTGGGTTCAGGA | TAAAACAGGGTGTCTGGGGA |
| BIRC2(cIAP1) | GAATCTGGTTTCAGCTAGTCTGG | GGTGGGAGATAATGAATGTGCAA |
| IFNβ | GTCTCCTCCAAATTGCTCTC | ACAGGAGCTTCTGACACTGA |
| BCL-X-Long | CATGGCAGCAGTAAAGCAAG | TGCTGCATTGTTCCCATAGA |
| BIRC3(cIAP2) | AAGCTACCTCTCAGCCTACTTT | CCACTGTTTTCTGTACCCGGA |
| Bcl-2 | GAGGATTGTGGCCTCTTTG | ACAGTTCCACAAAGGCATCC |
| c-FLIP | AATTCAAGGCTCAGAAGCGA | GGCAGAAACTCTGCTGTTCC |
| gadd45β | ACAGTGGGGGTGTACGAGTC | TTGATGTCGTTGTCACAGCA |
| TRAF1 | AGAACCCGAGGAATGGCGA | TGAAGGAGCAGCCGACACC |
| TRAF2 | AGGTCTGCCCCAAGTTCCC | GCTGTTTCTCACCCTCTACCGT |
| A1/Bf1-1 | CAGGCTGGCTCAGGACTATC | TGTTCTGGCAGTGTCTACGG |
| IL8 | GTCCTTGTTCCACTGTGCCT | GCTTCCACATGTCCTCACAA |
| IL-1α | TGGCTCATTTTCCCTCAAAAGTTG | AGAAATCGTGAAATCCGAAGTCAAG |
| IL-1β | ACGAATCTCCGACCACCACT | CCATGGCCACAACAACTGAC |
| TNF-α | CCCCAGGGACCTCTCTCTAATC | GGTTTGCTACAACATGGGCTAC A |
| A20 | TCCTCAGGCTTTGTATTTGAGC | TGTGTATCGGTGCATGGTTTTA |
| IL-6 | GTGTGAAAGCAGCAAAGAG | CTCCAAAAGACCAGTGATG |
| IL-12 | TGGAGTGCCAGGAGGACAGT | TCTTGGGTGGGTCAGGTTTG |
| COX2 | TTCTCCTTGAAAGGACTTATGGGTAA | AGAACTTGCATTGATGGTGACTGTTT |
| MIP2(CXCL2) | TTCACAGTGTGTGGTCAACATTT | TCTGCTCTAACACAGAGGGAAAC |
| VCAM-1 | TGGGCTGTGAATCCCCATCT | GGGTCAGCGCGTGGAATTGGTC |
| uPA | ATCTGCCTGCCCTCGATGTATAA | TTTCAGCTGCTCCGGATAGAGATAG |
| BLC | ACTCTGCTAATGAGCCTGGAC | CCTTGGACTGGAGAGAGGCT |
| ELC(CCL19) | CCATCCCTGGGTACATCGTG | GCAGTCTCTGGATGATGCGT |
| SLC | GTCTCCCAGGGAGCATGAGA | GGGAGCCGTATCAGGTCCA |
| SDF-1α | ACTAAAACCTTGTGAGAGATGA | GGGTCTAAATGCTGCAAACCT |
| BAFF | GGCAGGTACTACGACCATCTC | TGGGCCTTTTCTCACAGAAGT |
| ICAM1 | CCCATGAAACCGAACACAC | ACTCTGTTCAGTGTGGCACC |
| MIP-1α | ATGCAGGTCTCCACTGCTG | TCAGGCACTCAGCTCCAG |
| CXCL1 | AGGGAATTCACCCCAAGAAC | CACCAGTGAGCTTCCTCCTC |
| CCL2 | CTTCTGTGCCTGCTGCTCAT | CGGAGTTTGGGTTTGCTTGTC |
| IP10 | GGGAGCAAAATCGATGCAGTGCT | GCAGCCTCTGTGTGGTCCATCC |
| IFNα | CCTGATGAAGGAGGACTCCATT | AAAAAGGTGAGCTGGCATACG |
| CCL4(MIP1β) | GCTAGTAGCTGCCTTCTGCTCTCC | CAGTTCCAGCTGATACACG TACTCC |
| CCL5 | CTGCTGCTTTGCCTACATTGC | GTTCAGGTTCAAGGACTCTCCATC |
| CXCL10 | AAGCAGTTAGCAAGGAAAGGTC | TTGAAGCAGGGTCAGAACATC |
| IL-2 | GAACTAAAGGGATCTGAAACAACATTC | TGTTGAGATGATGCTTTGACAAAA |
| IL-4 | TGCTTCCCCCTCTGTTCTTCCT | GGCAGCGAGTGTCCTTCTCATG |
| IL-5 | AGCCATGAGGATGCTTCTGC | AAGCAGTGCCAAGGTCTCTT |
| IL-10 | GCCTAACATGCTTCGAGATC | CTCATGGCTTTGTAGATGCC |
| CDK4 | AGTTCGTGAGGTGGCTTTA | GGGTGCCTTGTCCAGATA |
| GMCSF | TCAGGATGGTCATCTTGGAG | TCTTCTGCCATGCCTGTATC |
| IκBα | CTCCGAGACTTTCGAGGAAATAC | GCCATTGTAGTTGGTAGCCTTCA |
| NF-κB(p50) | CCTGGATGACTCTTGGGAAA | TCAGCCAGCTGTTTCATGTC |
| NF-κB(p52) | GAACAGCCTTGCATCTAGCC | TTTTCAGCAT GGATGTCAGC |
| p65(RelA) | TCTGCTTCCAGGTGACAGTG | GCCAGAGTTTCGGTTCACTC |
| c-Rel | CGAACCCAATTTATGACAAC | TTTTGTTTCTTTGCTTTATTGC |
| RelB | CTGCTTCCAGGCCTCATATC | CGCAGCTCTGATGTGTTTGT |
| TLR4 | AGAAGCAGTGAGGATGATGCC | TTCTGTGTGGTTTAGGGCCA |
| MYD88 | GAAGCCTAGAGGCCATTCTG | GGCTTGTGATCTCAGGTGAA |
| TRAF6 | CACGTGGATACCAACTGCTC | TGTGTGCATCTCCTGTCTTG |
Figure 7Schematic diagram depicting the immunomodulatory mechanism of O-acetylated glucomannan.